Hanmi Science CEO Kim Jae-kyo announced an organizational overhaul and delivered his first message to employees on the company's internal computer network on Tuesday.
Hanmi Science CEO Kim Jae-kyo
“The Hanmi Group is on the verge of a new beginning,” Kim said in the message, titled “Hanmi, a powerhouse in new drug development, faces time to leap forward as a global big pharma.”
“We have been leading the Korean pharmaceutical industry as an icon of ‘challenge and innovation’ for the past 50 years, and we are now taking on a new challenge of ‘innovative global drug development,’” he said.
Citing the DNA of “creation” and “challenge” and the spirit of “innovation” to lead the way, CEO Kim called for the company to become a “living pharmaceutical company” that develops new drugs that have never existed worldwide.
“With Hanmi Science as the holding company, Hanmi Pharmaceutical as the core business company, and 30 affiliated companies working together organically, we must further strengthen Hanmi's identity as a 'master of new drug development,’” Kim said. “The synergy between these group companies will enhance the Hanmi Group's future value and increase shareholder value.”
In conclusion, Kim said, “Inheriting the will of our founder, who wanted to make better medicines with our technology, let's strive to become a global big pharma. I hope everyone will join us on this daunting journey, and let's create a new vision of the Hanmi Group together.”
Earlier in the day, the Hanmi Group announced a major organizational reshuffle to establish and operate its mid- to long-term business strategy. The reorganization aimed to strengthen organic linkages between the holding company and business companies and prepare a strategic system for creating future growth engines.
The group has established the Planning & Strategy Division and Innovation Division within the holding company, Hanmi Science. Group officials explained that it has reorganized the innovation-focused organization to quickly respond to the rapidly changing global healthcare industry and maximize future business discovery and strategic growth opportunities.
The Planning & Strategy Division comprises the Management and Business Strategy teams. The Management Strategy Team establishes mid- to long-term strategies for the group and its affiliates and promotes new growth business plans. According to the officials, the business strategy team expands opportunities through various strategic investments and systematic management to increase the chances of success.
The Innovation Headquarters, comprised of the C&D (Connect & Development) Strategy Team, L&D (Launching & Development) Strategy Team, and IP Team, plays a key role in strengthening the group's open innovation and licensing strategies and further enhancing global commercialization strategies, including internal technology and product licensing out.
Hanmi Group also announced that it had consolidated its staff organizations, which were operated separately, to improve work efficiency and establish a more systematic support system.